On December 24, 2024, Sanjay Shrivastava, a Director at enVVeno Medical Corp (NVNO, Financial), purchased 5,400 shares of the company, as reported in the SEC Filing. Following this transaction, the insider now holds a total of 9,288 shares in the company.
enVVeno Medical Corp is a company focused on the development of innovative medical devices for the treatment of venous disease. The company's primary product is designed to address chronic venous insufficiency, a condition that affects millions of people worldwide.
The recent purchase by the insider is part of a broader trend within the company. Over the past year, there have been three insider buys and one insider sell. This activity may indicate a level of confidence in the company's future prospects from those within the organization.
On the day of the purchase, shares of enVVeno Medical Corp were trading at $2.90 each, resulting in a market cap of $53.661 million. This transaction marks the insider's total purchase of 5,400 shares over the past year, with no shares sold during this period.
For investors, insider buying can be a signal worth noting, as it often reflects the insider's belief in the company's potential. However, it is essential to consider other factors such as the company's GF Value, price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow when evaluating the stock's potential.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
